2 months ago
APGE
AnalystsAkash TewariAkash Tewari's Stock Forecasts
AnalystsAkash Tewari
Analyst Ranking
Top 29%
#1327 out of 4565 analysts
Average Return
+3.13%
Win Rate
43%16 out of 37
Risk vs Reward
Poor
Good
Akash Tewari's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Global Blood Therapeutics IncGBT | +139.48% | $27.81 | $66.60 | 2021-10-06 - 2022-08-08 | Strong Buy |
Apogee Therapeutics IncAPGE | +113.70% | $21.46 | $45.86 | 2023-08-07 - 2024-04-25 | Strong Buy |
Apogee Therapeutics IncAPGE | +113.70% | $21.46 | $45.86 | 2023-08-07 - 2024-04-25 | Strong Buy |
Spyre Therapeutics IncSYRE | +79.89% | $18.05 | $32.47 | 2023-12-10 - 2024-04-25 | Strong Buy |
Cytokinetics IncCYTK | +64.33% | $22.82 | $37.50 | 2021-03-11 - 2022-03-11 | Buy |
Akash Tewari Analyst Color
Get additional color on Akash Tewari's coverage of popular stocks
3 months ago
APLS
6 months ago
PFE
9 months ago
LLY
9 months ago
LLY
a year ago
LLY
a year ago
PFE
a year ago
ZYME
a year ago
BMRN
3 years ago
BNTX
Akash Tewari's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Alkermes PLCALKS | 2 | Strong Buy | $50.00 | +104.58% | Maintains | 17 days ago |
Apogee Therapeutics IncAPGE | 4 | Strong Buy | $75.00 | +63.54% | Maintains | 2 months ago |
Apellis Pharmaceuticals IncAPLS | 1 | Strong Buy | $80.00 | +66.91% | Upgrades | 3 months ago |
Spyre Therapeutics IncSYRE | 1 | Strong Buy | $31.00 | -4.53% | Initiates Coverage On | 4 months ago |
Arvinas IncARVN | 2 | Strong Buy | $40.00 | +26.58% | Upgrades | 5 months ago |
Regeneron Pharmaceuticals IncREGN | 4 | Strong Buy | $937.00 | +5.20% | Maintains | 5 months ago |
Acelyrin IncSLRN | 2 | Strong Buy | $12.00 | +183.02% | Maintains | 5 months ago |
Pfizer IncPFE | 2 | Strong Buy | $39.00 | +54.39% | Upgrades | 6 months ago |
Eli Lilly & CoLLY | 4 | Strong Buy | $615.00 | -15.16% | Upgrades | 9 months ago |
Enanta Pharmaceuticals IncENTA | 2 | Hold | $18.00 | +44.23% | Downgrades | 9 months ago |
Argenx SeARGX | 2 | Strong Buy | $513.00 | +39.18% | Maintains | 9 months ago |
Terns Pharmaceuticals IncTERN | 1 | Strong Buy | $18.00 | +287.93% | Initiates Coverage On | a year ago |
Relay Therapeutics IncRLAY | 2 | Hold | $12.50 | N/A | Upgrades | a year ago |
Merck & Co IncMRK | 1 | Strong Buy | $125.00 | N/A | Initiates Coverage On | a year ago |
Bristol Myers Squibb CoBMY | 1 | Hold | $62.00 | N/A | Initiates Coverage On | a year ago |
Zymeworks IncZYME | 1 | Strong Buy | $11.00 | N/A | Upgrades | a year ago |
Third Harmonic Bio IncTHRD | 2 | Hold | $3.60 | N/A | Downgrades | a year ago |
Acrivon Therapeutics IncACRV | 1 | Strong Buy | $17.00 | N/A | Initiates Coverage On | a year ago |
Biomarin Pharmaceutical IncBMRN | 1 | Strong Buy | $120.00 | N/A | Maintains | a year ago |
Eqrx IncEQRX | 2 | Hold | $3.20 | N/A | Downgrades | a year ago |
Global Blood Therapeutics IncGBT | 3 | Hold | $68.50 | N/A | Downgrades | 2 years ago |
Neurocrine Biosciences IncNBIX | 1 | Strong Buy | $112.00 | N/A | Assumes | 2 years ago |
Cytokinetics IncCYTK | 2 | Strong Buy | $75.00 | N/A | Initiates Coverage On | 3 years ago |
Madrigal Pharmaceuticals IncMDGL | 1 | Strong Buy | $151.00 | N/A | Initiates Coverage On | 3 years ago |
Exelixis IncEXEL | 2 | Strong Buy | $28.00 | N/A | Initiates Coverage On | 3 years ago |
Acceleron Pharma IncXLRN | 2 | Hold | $180.00 | N/A | Initiates Coverage On | 3 years ago |
Biontech SeBNTX | 1 | Hold | $230.00 | N/A | Initiates Coverage On | 3 years ago |
Horizon Therapeutics Public Ltd CoHZNP | 1 | Buy | $107.00 | N/A | Initiates Coverage On | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.